The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Breast Cancer Statistics, 2022
Open accessAbstract
This article is the American Cancer Society’s update on female breast cancer statistics in the United States, including population‐based data on incidence, mortality, survival, and mammography screening. Breast cancer incidence rates have risen in most of the past four decades; during the most recent data years (2010–2019), the rate increased by 0.5% annually, largely driven by localized‐stage and hormone receptor‐positive disease. In contrast, breast cancer mortality rates have declined steadily since their peak in 1989, albeit at a slower pace in recent years (1.3% annually from 2011 to 2020) than in the previous decade (1.9% annually from 2002 to 2011). In total, the death rate dropped by 43% during 1989–2020, translating to 460,000 fewer breast cancer deaths during that time. The death rate declined similarly for women of all racial/ethnic groups except American Indians/Alaska Natives, among whom the rates were stable. However, despite a lower incidence rate in Black versus White women (127.8 vs. 133.7 per 100,000), the racial disparity in breast cancer mortality remained unwavering, with the death rate 40% higher in Black women overall (27.6 vs. 19.7 deaths per 100,000 in 2016–2020) and two‐fold higher among adult women younger than 50 years (12.1 vs. 6.5 deaths per 100,000). Black women have the lowest 5‐year relative survival of any racial/ethnic group for every molecular subtype and stage of disease (except stage I), with the largest Black–White gaps in absolute terms for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative disease (88% vs. 96%), hormone receptor‐negative/human epidermal growth factor receptor 2‐positive disease (78% vs. 86%), and stage III disease (64% vs. 77%). Progress against breast cancer mortality could be accelerated by mitigating racial disparities through increased access to high‐quality screening and treatment via nationwide Medicaid expansion and partnerships between community stakeholders, advocacy organizations, and health systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
Self-citationSiegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Self-citationAmin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., & Winchester, D. P. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21388 · Cited by 6,502
Breast Cancer Treatment: A Review
Waks, A. G., & Winer, E. P. (2019) · JAMA · doi:10.1001/jama.2018.19323 · Cited by 4,804
Cancer treatment and survivorship statistics, 2022
Miller, K. D., Nogueira, L., Devasia, T., Mariotto, A. B., Yabroff, K. R., Jemal, A., Kramer, J., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21731 · Cited by 3,597
Self-citationPembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Cancer treatment and survivorship statistics, 2012
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., Cooper, D., Gansler, T., Lerro, C., Fedewa, S., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21149 · Cited by 2,928
Self-citationTrastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., Tsurutani, J., Ueno, N. T., Prat, A., Chae, Y. S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203690 · Cited by 2,664
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814017 · Cited by 2,625
Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
Berry, D. A., Cronin, K. A., Plevritis, S. K., Fryback, D. G., Clarke, L., Zelen, M., Mandelblatt, J. S., Yakovlev, A. Y., Habbema, J. D. F., & Feuer, E. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050518 · Cited by 2,460
Research works printed but not linked: 11
- Centers for Disease Control and Prevention, 2019, Behavioral Risk Factor Surveillance System Survey Data 2019
- 10.1002/cncr.32472 · doi:10.1002/cncr.32472
- 10.1158/1055-9965.EPI-20-1528 · doi:10.1158/1055-9965.epi-20-1528
- Hamilton BE, 2022, Births: Provisional Data for 2021. Vital Statistics Rapid Release Report No. 20. Division of Vital Statistics, National Center for Health, Statistics
- 10.1016/j.jamcollsurg.2019.12.004 · doi:10.1016/j.jamcollsurg.2019.12.004
- 10.1002/jso.25315 · doi:10.1002/jso.25315
- 10.1001/jamasurg.2020.0322 · doi:10.1001/jamasurg.2020.0322
- 10.1016/j.semradonc.2022.01.004 · doi:10.1016/j.semradonc.2022.01.004
- 10.1245/s10434-018-6531-5 · doi:10.1245/s10434-018-6531-5
- 10.1001/jamasurg.2018.5113 · doi:10.1001/jamasurg.2018.5113
- American Cancer Society. Table 6B. Up‐to‐Date Mammography Prevalence (%) by State US 2020.Cancer Prevention & Early Detection Facts & Figures Tables and Figures 2022. American Cancer Society; 2022:32. Accessed July 1 2022.cancer.org/content/dam/cancer‐org/research/cancer‐facts‐and‐statistics/cancer‐prevention‐and‐early‐detection‐facts‐and‐figures/cped‐2022‐tables‐and‐figures.pdf
Cited by
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Self-citationSiegel, R. L., Giaquinto, A. N., & Jemal, A. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21820 · Cited by 9,533
Self-citationBreast cancer: pathogenesis and treatments
Xiong, X., Zheng, L.-W., Ding, Y., Chen, Y.-F., Cai, Y.-W., Wang, L.-P., Huang, L., Liu, C.-C., Shao, Z.-M., & Yu, K.-D. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02108-4 · Cited by 958
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Ye, F., Dewanjee, S., Li, Y., Jha, N. K., Chen, Z.-S., Kumar, A., Vishakha, Behl, T., Jha, S. K., & Tang, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01805-y · Cited by 554
Notch signaling pathway in cancer: from mechanistic insights to targeted therapies
Shi, Q., Xue, C., Zeng, Y., Yuan, X., Chu, Q., Jiang, S., Wang, J., Zhang, Y., Zhu, D., & Li, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01828-x · Cited by 401
Fahim, Y. A., Hasani, I. W., Kabba, S., & Ragab, W. M. (2025) · European Journal of Medical Research · doi:10.1186/s40001-025-03196-w · Cited by 329
Rao, A., Kim, J., Kamineni, M., Pang, M., Lie, W., Dreyer, K. J., & Succi, M. D. (2023) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2023.05.003 · Cited by 278
Evaluating ChatGPT as an Adjunct for Radiologic Decision-Making
Rao, A., Kim, J., Kamineni, M., Pang, M., Lie, W., & Succi, M. D. (2023) · doi:10.1101/2023.02.02.23285399 · Cited by 257
Uses and Limitations of Artificial Intelligence for Oncology
Kolla, L., & Parikh, R. B. (2024) · Cancer · doi:10.1002/cncr.35307 · Cited by 126
Oikonomou, E. K., Sangha, V., Dhingra, L. S., Aminorroaya, A., Coppi, A., Krumholz, H. M., Baldassarre, L. A., & Khera, R. (2025) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.124.011504 · Cited by 60
Adam, M., & Baroudi, U. (2024) · IEEE Open Journal of the Communications Society · doi:10.1109/ojcoms.2024.3506214 · Cited by 46
Hu, H., Zheng, S., He, C., Zheng, Y., Wei, Q., Chen, S., Wu, Z., Xu, Y., Zhao, B., & Yan, C. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02502-8 · Cited by 43
Nanosensitizer-assisted sonodynamic therapy for breast cancer
Yu, J., Hu, J.-R., Tian, Y., Lei, Y.-M., Hu, H.-M., Lei, B.-S., Zhang, G., Sun, Y., & Ye, H.-R. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03311-3 · Cited by 43
A tumor cell exosome-mimicking multifunctional nanozyme for targeted breast cancer radiotherapy
Chen, G., Jiang, D., Ding, S., Huang, C., Zhu, D., & Jiang, H. (2023) · Nanoscale · doi:10.1039/d3nr03065b · Cited by 31
An ensembled framework for human breast cancer survivability prediction using deep learning
Mustafa, E., Jadoon, E. K., Khaliq-uz-Zaman, S., Humayun, M. A., & Maray, M. (2023) · Diagnostics · doi:10.3390/diagnostics13101688 · Cited by 24
GSH/pH dual response drug delivery system for photothermal enhanced gene-immunotherapy
Ma, T., Li, W., Ye, J., Huang, C., Li, Y., Qiu, H., & Yin, S. (2023) · Nanoscale · doi:10.1039/d3nr03881e · Cited by 21
Iqbal, H., Inam‐Ur‐Raheem, M., Munir, S., Rabail, R., Kafeel, S., Shahid, A., Mousavi Khaneghah, A., & Aadil, R. M. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.3869 · Cited by 19
Ye, Q., Zhou, X., Ren, H., Han, F., Lin, R., & Li, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1274336 · Cited by 15
Mageau, E., Derbowka, R., Dickinson, N., Lefort, N., Kovala, A. T., Boreham, D. R., Tai, T. C., Thome, C., & Tharmalingam, S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47080589 · Cited by 12
Metadata
- Authors
- Giaquinto, A. N., Sung, H., Miller, K. D., Kramer, J. L., Newman, L. A., Minihan, A., Jemal, A., & Siegel, R. L.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2022-10-03
- Volume
- 72
- Issue
- 6
- Pages
- 524-541
- ISSN
- 0007-9235 (ISSN-L)
- 1542-4863
- OpenAlex
- W4300690596
- Cited by
- 2,286
- References
- 90
- FWCI
- 190.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.